Aflac President: why AI shouldn’t drive your healthcare

A recent study found 76% of Gen Z adults and 63% of millennials use AI as their first source of primary-healthcare information before consulting a doctor. Aflac President Virgil Miller argues that AI should support, rather than replace, physician care and cancer-screening decisions, noting that nearly two-thirds of Americans delay recommended screenings. The commentary highlights a potential role for AI in patient education while emphasizing that delayed diagnoses remain relevant to Aflac's cancer-insurance business.

Analysis

This is corporate advocacy rather than a measurable operating update, so it should not alter AFL estimates absent claims or enrollment data. The relevant economic tension is that broader screening can increase near-term diagnosis incidence and accelerate claim recognition for cancer indemnity products, while potentially improving treatment outcomes without proportionately reducing AFL's lump-sum benefit exposure. Any screening-led claims-frequency uptick would matter most if it outpaces pricing, underwriting assumptions, and reserve development.

AI health engagement is more plausibly an expense and distribution opportunity than a near-term demand catalyst: better member navigation could lower servicing costs and improve cross-sell conversion, but consumer-facing AI advice has no demonstrated link here to policy attach rates or persistency. The more consequential second-order risk is regulatory and reputational—an AI-enabled claims, underwriting, or care-navigation product would face heightened scrutiny if it is perceived as steering patients, delaying care, or using health data for pricing.

Near term, the market should remain focused on AFL's benefit ratio, premium growth, persistency, and Japan capital/FX translation rather than awareness-season commentary. Over 6-18 months, a sustained rise in early diagnoses could be a modest reserve and pricing issue for supplemental cancer carriers, but AFL's ability to reprice new business and maintain lapse rates determines whether this becomes margin dilution or merely a pass-through premium adjustment.

Key Decisions for Investors

• No standalone trade: maintain neutral AFL exposure until the next earnings release provides cancer-policy sales, claims-frequency, benefit-ratio, and reserve-development evidence; the article alone has insufficient signal for an estimate revision.
• Set an alert for a sequential increase in AFL's U.S. benefit ratio or adverse reserve development that management attributes to screening or diagnosis mix. A sustained 100bp-plus deterioration without offsetting pricing would justify reassessing long exposure over the following 1-3 quarters.
• For existing AFL longs, treat persistency and new-policy pricing as the key falsifiers of the benign thesis: weaker retention alongside higher claims frequency would create operating leverage to the downside and could pressure the valuation multiple.
• Monitor announced AI partnerships for whether they are limited to education/navigation versus claims or underwriting. The latter would be a potential efficiency catalyst, but also raises execution and regulatory risk; wait for disclosed cost savings or conversion metrics before assigning value.